So you consider people who are open and honest to be losers. That pretty much sums up your character.

Breakout time..., finally.

You still don't get it. RS was to $1 per share. Factor ALL dilution since and you get .10 per share round numbers. The company is worth more now than when the RS occured. Reducing debt at a rate of $4 million PY. Reduced interest cost by $1.5 million PY through debt restructuring. More restructuring of debt and "other securities" happening as we speak. RNVA is artificially dilututed due to OTC market conditions (including disproportional short selling). Artificial dilution cleans up fast and easy. Most investors want to see RNVA repilicate the CAH model at Jamestown and elsewhere, in which case cancelling shares would throw a wet blanket on growth.

Debt reduction on a $4 million PY pace plus $1.5 million PY in interest savings from debt restructuring plus more restructuring of debt and "other securities" in the works.(10/25) Ridiculously undervalued.

FYI: Corporate buybacks are not subject to SEC insider trading disclosure requirements. No advance or immediate reporting required. No 90 day minimum cooling off period. A company may disclose only in its quarterly and annual reports, or it may also wait until all buybacks are completed and then release the info.

https://www.davispolk.com/insights/client-update/sec-mandates-new-disclosures-stock-buybacks

Strong buy recommendation on RNVA from God.

News coming anytime on the following:
- Q4 revenues $4.5 to $5.5 million? "Lagan responded that the current operations plus the behavioral health business should give the Company an annualized run rate of $25-30 million by year end. (08/21)
- Corporate equity buyback and/or more debt reduction to add to more than $2 million reduced through Q3? “The debt restructuring improves our balance sheet and will save approximately $1.5 million in interest expense annually. In addition, we are in discussions about other potential modifications to debt and other securities in the hope we can secure additional amendments that further improve our overall financial position.” (10/25)
- Jamestown CAH approval? "He (Lagan) went on to remind Davis that there were still some items to be fixed from previous more difficult days but explained the intention to formulate a plan before year end to duplicate the current (Critical Access Hospital) model in the Jamestown facility in 2024, and stated that if that was successful it would be possible to leave 2024 with annualized revenues of $50-60 million. (08/21)

Best oif all New Years to you! Will be wild.

.0025/.025/.25. That will work for now. Can adjust based on annual report, company guidance, and other events. Penny stock in 2025.

No time of trade registered for the last 30-40 million traded. Very interesting.

Steady around .004 for months. Good volume today. More BS.

2023 debt reductions + $1.25 million PY debt cost reduced (10/25 debt restructure) = roughly the value of the entire OS at .0001. RNVA is the no brainer of 2024.

RNVA paid off $2.34 million in debt in the first three quarters of 2023. You don't know what you are talking about.

Subsequent earnings report have already proven you wrong. Keep on talking the price down, whatever your motive. RNVA investors' day is coming soon.

That article was(is) 100% right. In a more bullish OTC market, RNVA would have only tested the high 000s at worts before the support came in. RNVA has been long oversold and undervalued. The stock is artificially diluted due to disproportionate short selling. $4 million buys the entire OS and more. RNVA is a solid value investment just playing the price correction.

But the ask has been gradually shrinking over the last two or three weeks overall as the breakthrough draws near.

Could get active about now as close out the last week of 2024. We'll see.

Nope, the alarm went off when CAH revenues started rolling in. All is more inevitable than you see on the surface.
https://www.hrsa.gov/sites/default/files/hrsa/opa/critical-access-hospital-factsheet.pdf
https://www.ruralhealthinfo.org/topics/critical-access-hospitals

https://curallo.com/

According to company guidance, RNVA is just now reaching an "annualized run rate" of $25-30 million in revenue, meaning $6.25-7.25 million in Q1 2024 revenue from current operations. More restructuring of debt and "other securities" (corporate equity buyback?) is also in the works according to the October 25 press release, likely to involve the payoff or pay down of the $2.5 million note to INQR receivable and last extended to the end of this year. Something should break on that after the first RNVA board meeting in 2024. Jamestown reopening under the CAH model (which will then double RNVA revenue YOY) is also in the works with news on that dues sometime during Q1 2024, if not any day now.

That's the bet based on current information.

OTC market volume has been pretty thin for a couple of years now. I think market volume is due to increase soon.

Right. If Seamus has an apple, he must have an orange too. CEOs don't determine day to day and hour to hour volume. Nonsense.

$6 million or more in Q1 2024..., easy.

Meaning Q4 revenue $4-5 million, given Myrtle outpatient services only began in November.

Company guidance 8/21:
"Lagan stated that it was good to see the facility opened and repeated that he believed this business would fit well with hospital operations. He went in to say that when operating at full potential this first facility for Myrtle should generate $4 - $5 million in profitable revenues a year.

Davis then mentioned the fast approaching year end and suggested that the Company could be leaving 2023 with annualized revenues in the $25-30 million range and be profitable. He asked Lagan how he intended to deliver continued growth and where he saw the Company a year from now.

Lagan responded that the current operations plus the behavioral health business should give the Company an annualized run rate of $25-30 million by year end. He went on to remind Davis that there were still some items to be fixed from previous more difficult days but explained the intention to formulate a plan before year end to duplicate the current model in the Jamestown facility in 2024, and stated that if that was successful it would be possible to leave 2024 with annualized revenues of $50-60 million. He confirmed his belief that this was achievable."

RNVA news next.

Who cares? Insider buying is always good.

INQRs CEO bought 50,000 INQR shares on December 12.
https://archive.fast-edgar.com/20231218/AQ2ZV22CZZ2RD2TN22942MY2PS24ZZ22ZV52/

What INQR is already doing lets Rennova/Myrtle Recovery Center patients schedule their own appointments, which saves RNVA some admin costs. The new program will be a key part of outpatient services (especially through Myrtle Recovery Center) which began last month. 2024 belongs to RNVA shareholders! (If not for the bear 2023 OTC market, RNVA would have already broken out of the 000s.)

Just what I was saying yesterday. As INQR gets synergy from RNVA growth (including the new Myrtle Recovery Center and upcoming Jamestown reopening), capital returns to RNVA shareholders. That was a pretty strong hint about the $2.5 million note from RNVA which is now receivable. Do the math on the share structure improvements, "reestructuring of debt and other securites, that was already under discussion as of the last company update. $2.5 million!

"We are cognizant of the previous and continued reliance on our former parent, Rennova Health, Inc. (RNVA), as a customer and source of funding and we are determined that 2024 will see that support, while appreciated, much less critical or important for our continued success."

Resructured debt so far adds $1.5 million PY to the P/L bottom line. More financial restructuring (related to INQR financing and RNVA profit ) will improve RNVA share structure. Jamestown reopening will double the size of the company. Company turnaraound equals stock rebound.

RNVA is the parent company. The $2.5 million note receivable and those preferred share series are clearly in play in RNVAs financial restructuring. Who knows yet exactly what is being negotiated, but investors need to be aware that improvements in the RNVA share structure are happening as we speak.

More restructuring of debt and "other securities" in the works according to the same release. The $2.5 million Innovaqor note is a receivable. Synergy built in as INQR revenue to soar along with RNVA upon Jamestown reopening. Company guidance already points to record Q4 revenue. Buyback of corporate equity in some form appears inevitable.

RNVA should follow a (revenue-driven) pattern similar to DPLS.

See DPLS '20-21 revenue-driven breakout chart.

Expecting news on:
- More restructuring of debt and "other securities." ($2.5 million note receivable)
- Reaffirming previous company guidance for record revenues in Q4 including new revenue post-opening of the Myrtle Recovery Center.
- Reopening the Jamestown hospital under the CAH model. (Jamestown did $86 million PY in revenue before closing. Company guidance suggests $30-40 million PY from CAH reimbursable services after reopening.)

This link is still a good source for 000 chart reads based on historical OTC market data: http://www.stockta.com/cgi-bin/analysis.pl?symb=RNVA&cobrand=&mode=stock

When major indices break records, investors begin looking for bargains OTC. RNVA is the bargain hunter's dream and the bottom feeder's cream.

$2.5 million worth of corporate equity is in one note receivable. That is clearly in play in the CEOs ongoing restructuring of debt and "other securities." Balance sheet and share structure improvements happening as we speak. Buy 'em.

Corporate equity shifted from (some) preferred shares to common shares. The dilution happened a long time ago when the preferred share agreement was made. A larger percentage of corporate equity is now in common shares. I'm okay with that.